Mallinckrodt Pharmaceuticals has partnered with the Washington University School of Medicine in St. Louis to fund up to $10 million over five years in support of rare-disease research projects, according to an announcement on Monday.
The partnership is aimed at pursuing new therapies for patients with complex medical conditions, or rare diseases with few or no treatment options.
The pharmaceutical company, which has its U.S. headquarters in the St. Louis area, will fund projects that show promise in developing new drugs or basic research that is likely to have medical applications. The grants will be awarded on a competitive basis, selected by a committee from the school of medicine and Mallinckrodt.
The grant program will consist of two types of funding, program grants and challenge grants. The program grants will award up to $750,000 per year for projects with a likelihood of moving an investigational therapy into the clinic. The challenge grants will fund up to $150,000 to $300,000 annually for laboratory research that is deemed likely to have future medical applications.
Faculty with funded projects will have access to Mallinckrodt resources, including including analytical chemistry tools and expertise and drug formulation support.